# Efficacy and Safety of Oral Roflumilast Taken Once Daily in Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (BY217/M2-119)

> **NCT00242320** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 551 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** Roflumilast
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00242320
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2007-05
- **Final completion:** 2007-08
- **Target enrollment:** 551 (ACTUAL)
- **Last updated:** 2016-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00242320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00242320, "Efficacy and Safety of Oral Roflumilast Taken Once Daily in Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (BY217/M2-119)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00242320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*